References
- Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820–37
- Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618–24
- Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005;128:2238–46
- Koch H, Landen H, Stauch K. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: evidence from a post-marketing surveillance study of 1467 patients. Clin Drug Investig 2004;24: 441–8
- Finch R, Schurmann D, Collins O. Randomised controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Chemotherapy 2002;46:1746–54
- Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004;27:395–405
- Welte T, Petermann W, Schurmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41:1697–705
- Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128:3398–406
- Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006;42:73–81
- Barth J, Stauch K, Landen H. Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillancestudy withintravenous moxifloxacin in hospital practice. Clin Drug Investig 2005;25:691–700
- Read RC, Torres A, Lode H. Clinical cure rates and infection types in the Moxifloxacin Treatment IV (MOTIV) study in hospitalised patients with community-acquired pneumonia (CAP). Clin Infect Dis 2008; in press
- Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243–50
- Rote Liste service GmbH. Rote Liste. Available from http://www.rote-liste.de/ [Last accessed Oct 7 2007]
- Wirtz C. Harmonised Indices of Consumer Prices: November 2006. Statistics in Focus: Economy and Finance. Eurostat, 2006
- DGK-NT 2005 Full Costs (German Hospital Federation fee scale), 2005
- Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40
- Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. London, United Kingdom: European Agency for the Evaluation of Medicinal Products; 2000. Report No.: CPMP/EWP/482/99
- Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124:526–35
- Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007;59:977–89
- Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138–80
- Fallpauschalen-Katalog G-DRG Version 2006, 2006